Intensity Therapeutics (INTS) Shares Outstanding (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Shares Outstanding (Entity) came in at $2.5 million in Q1 2026, up 316.07% YoY from $610595.0 in Q1 2025, and up 87.3% on a QoQ basis from $1.4 million in Q4 2025.
Intensity Therapeutics (INTS) Shares Outstanding (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Shares Outstanding (Entity) data on file, last reported at $2.5 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 316.07% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 316.07% YoY) and the FY2025 annual result came in at $1.4 million, up 124.22% from the prior year.
- Shares Outstanding (Entity) grew to $2.5 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $2.5 million in Q1 2026 to a low of $136404.0 in Q2 2022.
- A 5-year average of $691294.4 and a median of $548495.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) advanced 1.13% — and 2026, when it surged 316.07%.
- Tracing INTS's Shares Outstanding (Entity) over 5 years: stood at $136404.0 in 2022, then surged by 152.67% to $344653.0 in 2023, then surged by 75.51% to $604915.0 in 2024, then jumped by 124.22% to $1.4 million in 2025, then jumped by 87.3% to $2.5 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $2.5 million (Q1 2026), $1.4 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | 2.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.71 Mn |
| Mar 31, 2026 | 2.53 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 754,725.00 |
| Mar 31, 2025 | 606,928.00 |
| Dec 31, 2024 | 556,279.00 |
| Sep 30, 2024 | 552,186.00 |
| Jun 30, 2024 | 548,486.00 |
| Mar 31, 2024 | 548,379.00 |
| Dec 31, 2023 | 344,653.00 |
| Sep 30, 2023 | 546,425.00 |
| Jun 30, 2023 | 140,663.00 |
| Mar 31, 2023 | 136,404.00 |
| Dec 31, 2022 | 136,404.00 |
| Sep 30, 2022 | 136,404.00 |
| Jun 30, 2022 | 136,404.00 |